Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue
· thehindu.com
Cohance Lifesciences reports ₹45.19 crore Q1 loss due to lower revenue, despite growth in subsidiaries and API performance.
Contract development and manufacturing organisation (CDMO) Cohance Lifesciences (formerly Suven Pharmaceuticals) reported ₹45.19 crore loss on a consolidated ...